微轴流泵的隐藏风险:主动脉及无名动脉附壁血栓五例报告
该研究报道了2021至2025年间90例接受Impella 5.5作为心脏移植或持久LVAD桥接的患者中,5例(5.5%)发生主动脉或无名动脉附壁血栓。4例经血栓清除或保守治疗后成功接受移植或LVAD植入,1例死于栓塞性卒中。提示Impella 5.5支持期间存在未被充分认识的栓塞性卒中机制。
要点
- Impella 5.5桥接治疗中附壁血栓发生率为5.5%(5/90)。
- 附壁血栓可导致致命性栓塞性卒中。
- 需关注抗凝目标、装置撤除技术及栓塞并发症管理。
核心结论
- Impella 5.5作为心脏移植或持久LVAD桥接支持期间,主动脉或无名动脉附壁血栓是导致栓塞性卒中的未被充分认识的机制。
研究设计与样本
- 单中心病例系列,2021至2025年间90例接受Impella 5.5作为BTT或桥接至LVAD的患者中,报告5例主动脉或无名动脉附壁血栓。
主要发现
- 90例中5例(5.5%)发生附壁血栓。
- 4例经血栓清除或保守治疗后成功接受移植或LVAD植入。
- 1例发生致命性栓塞性卒中。
临床怎么用
- Impella 5.5桥接患者需警惕附壁血栓及栓塞性卒中风险。
- 抗凝目标、装置撤除技术和栓塞并发症管理需重新审视。
局限性
- 病例系列样本量小,仅报告5例事件,无法确立预防或治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surgically implanted microaxial flow pumps (Impella 5.5, Abiomed, Danvers, MA) are increasingly used as a bridge to heart transplantation (BTT) or bridge to durable left ventricular assist device (LVAD) implantation, yet thrombotic complications remain incompletely characterized. We report 5 cases of aortic or innominate mural thrombi during Impella 5.5 support. Among 90 patients supported with Impella 5.5 as a BTT or bridge to LVAD between 2021 and 2025, 5 (5.5%) developed mural thrombi. Four patients underwent successful transplantation or LVAD implantation following thrombectomy or conservative management, while 1 patient experienced a fatal embolic stroke. These findings highlight an under-recognized mechanism of embolic stroke in patients supported with Impella 5.5 as a BTT or bridge to LVAD, and raise important considerations regarding anticoagulation targets, device explant techniques, and management of embolic complications. Further investigation is warranted to establish prevention and treatment strategies for this growing challenge.
引用
- An KR, Elmously A, Lee J, et al. Hidden danger of microaxial flow pumps: Five cases of aortic and innominate mural thrombi. J Heart Lung Transplant. 2026. PMID: 41802550. doi:10.1016/j.healun.2026.02.1679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。